Due to the unprecedented nature of the COVID-19 pandemic, anyone reporting an Adverse Event and/or a Product Complaint via phone, should you receive a network busy signal (ie: if all lines busy/engaged) please continue to try your call throughout the day. Alternatively, you may email your Adverse Event to drugsafety@propharmagroup.com OR Product Complaint to productcomplaint@propharmagroup.com, OR medical information request to MedInfo@propharmagroup.com.

Calcium Gluconate in Sodium Chloride Injection

Therapeutic Category: Electrolyte Replenisher

INTRODUCING THE FIRST AND ONLY FDA APPROVED SINGLE-DOSE BAG FORMULATION

1,000 mg per 50 mL in a 100 mL Single-Dose Bag
2,000 mg per 100 mL in a 100 mL Single-Dose Bag

PATIENT READY

  • First and only single-dose bag formulation indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia1
  • Ready to store in an automated dispensing cabinet
  • 24-month shelf life at controlled room temperature storage
  • Saves time and increases efficiency with no need to compound
  • Bag and bag ports are free of natural rubber latex, DEHP and PVC2

To order WGCC products, please contact your wholesaler or call Customer Service at 1-888-493-0861.


NDC# Total Amount Fill Volume Concentration Container Type Pack Size Package Insert Barcodes
44567-620-24 1,000 mg 50 mL 20 mg/mL 100 mL Premix Bag 24 Bag Carton
44567-621-24 2,000 mg 100 mL 20 mg/mL 100 mL Premix Bag 24 Bag Carton

INDICATIONS AND USAGE:

Calcium Gluconate in Sodium Chloride Injection is a form of calcium indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia. Limitations of Use: The safety of Calcium Gluconate Injection for long term use has not been established. 

IMPORTANT SAFETY INFORMATION:

Contraindicated in hypercalcemia and in neonates receiving ceftriaxone. Warnings and Precautions: cardiac arrhythmias may occur with concomitant cardiac glycoside use; use caution when administering with ceftriaxone as a precipitate may form in the IV line; tissue necrosis and calcinosis may occur with or without extravasation; hypotension, bradycardia and cardiac arrhythmias may occur with rapid administration; contains aluminum which may cause toxicity. The most common adverse events are local soft tissue inflammation and necrosis; calcinosis cutis and calcification related to extravasation; vasodilation, decreased blood pressure, bradycardia, cardiac arrhythmia, syncope and cardiac arrest.

See package insert for complete prescribing information.

References:

  1. CALCIUM GLUCONATE IN SODIUM CHLORIDE Injection [package insert]  2. On file WG Critical Care, LLC

U.S. Patent Number: 10, 130, 646

WG Critical Care Product Catalog

To order WGCC products, please contact your wholesaler or call Customer Service at 1-888-493-0861.
© 2020 WG Critical Care, LLC | A PharmaSphere Company | 120 Rte 17 N, Paramus, NJ 07652